在即将到来的FDA关键决策之前,Hims & Hers Health Inc.已悄然展开肽类成分的测试工作。这家健康科技公司正密切关注监管机构是否允许针对这些药物进行配制。
在即将到来的FDA关键决策之前,Hims & Hers Health Inc.已悄然展开肽类成分的测试工作。这家健康科技公司正密切关注监管机构是否允许针对这些药物进行配制。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.